Skip Navigation

Annals of Oncology 2005 16(10):1563; doi:10.1093/annonc/mdi327
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content

© 2005 European Society for Medical Oncology

In this Issue

The first 10% of the full text of this article appears below.


   Pemetrexed/gemcitabine versus gemcitabine in pancreatic cancer
 
Pancreatic cancer accounts for more than 200 000 deaths worldwide each year, with most patients presenting with unresectable, locally advanced or metastatic disease. In multiple phase III studies in patients with pancreatic cancer, single-agent gemcitabine has shown response rates of 5.4–26%, median survival of approximately 6 months and 1-year survival of approximately 20%. Pemetrexed, a multitargeted antifolate, has demonstrated single-agent activity in pancreatic cancer with a response rate of 5.7%, median . . . [Full Text of this Article]


   Single-agent rituximab for follicular or mantle cell lymphoma
 

   Lung cancer mortality in European women
 

   Imatinib and hydroxyurea in glioblastoma multiforme
 

   Quote